8-azaprostaglandin derivative compound and agent comprising...

Details 8-azaprostaglandin derivative compound and agent comprising... 8-azaprostaglandin derivative compound and agent comprising...

C - Chemistry, Metallurgy

07

D

C07D 417/12 (2006.01) A61K 31/4015 (2006.01) A61K 31/4025 (2006.01) A61K 31/421 (2006.01) A61K 31/422 (2006.01) A61K 31/427 (2006.01) A61P 1/00 (2006.01) A61P 1/16 (2006.01) A61P 7/00 (2006.01) A61P 9/00 (2006.01) A61P 9/08 (2006.01) A61P 9/10 (2006.01) A61P 9/12 (2006.01) A61P 11/00 (2006.01) A61P 11/06 (2006.01) A61P 11/08 (2006.01) A61P 13/12 (2006.01) A61P 15/06 (2006.01) A61P 15/10 (2006.01) A61P 19/02 (2006.01) A61P 19/08 (2006.01) A61P 19/10 (2006.01) A61P 25/00 (2006.01) A61P 27/02 (2006.01) A61P 29

Patent

CA 2477715

8-Azaprostaglandin represented by the following general formula (I), pharmacologically acceptable salts thereof or cyclodextrin clathrates of the same: (I) wherein each symbol is as defined in the description. Because of strongly binding to PGE receptor subtype EP2, the compounds represented by the general formula (I) are useful in preventing and/or treating immune diseases, allergic diseases, nerve cell death, paramenia, premature birth, misbirth, baldness, retinal neuropathy such as glaucoma, erectile dysfunction, arthritis, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, hepatic injury, acute hepatitis, cirrhosis, shock, nephritis, renal insufficiency, circulatory diseases, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still~s disease, Kawasaki disease, burn, systemic granuloma, ulcerative colitis, Crohn~s disease, hypercytokinemia at dialysis, multiorgan failure, bone diseases and so on.

8-azaprostaglandine représentée par la formule générale (I), sels pharmaceutiquement acceptables de ce composé ou clathrates de cyclodextrine de celui-ci. Dans la formule, chaque symbole est tel que défini dans le descriptif. En raison de leur forte liaison au sous-type EP¿2? des récepteurs de la PGE, les composés représentés par la formule générale (I) sont utiles pour prévenir et/ou traiter des maladies immunitaires et allergiques, la mort neuronale, les troubles menstruels, un accouchement prématuré ou une fausse couche, la calvitie, la neuropathie rétinienne tel que le glaucome, le dysfonctionnement érectile, l'arthrite, des lésions pulmonaires, la fibrose pulmonaire, l'emphysème pulmonaire, la bronchite, la bronchopneumopathie chronique obstructive, des lésions hépatiques, l'hépatite aiguë, la cirrhose, l'état de choc septique, la néphrite, l'insuffisance rénale, des maladies circulatoires, le syndrome de réaction inflammatoire systémique, la septicémie, le syndrome hématophage, le syndrome d'activation des macrophages, la maladie de Still, la maladie de Kawasaki, les brûlures, le granulome systémique, la rectocolite hémorragique, la maladie de Crohn, l'hypercytokinémie lors de dialyse, la défaillance de plusieurs organes, des maladies osseuses, etc..

Affiliated with

Also associated with

Rating

8-azaprostaglandin derivative compound and agent comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 8-azaprostaglandin derivative compound and agent comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-azaprostaglandin derivative compound and agent comprising... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1815669